Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma

Journal of Trauma - Injury, Infection and Critical Care

Volumn 56, Issue 5, 2004, Pages 991-1000

  Majetschak, Matthias ^a,b,c   Cohn, Stephen M ^a   Obertacke, Udo ^b   Proctor, Kenneth G ^a   Block, Ernest F J ^d   Pruitt Jr , Basil A ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JACKSON MEMORIAL HOSPITAL   (United States)

^d NONE

Author keywords

Capillary leak; Endotoxin; Fluid requirements; Immunomodulation; Tumor necrosis factor

Indexed keywords

BOVINE SERUM ALBUMIN; ENDOTOXIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CAPILLARY LEAK SYNDROME; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR FRACTURE; FLUID THERAPY; HEMODYNAMICS; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION; INFLAMMATION; INJURY; LEUKOCYTE FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; SERUM; ANALYSIS OF VARIANCE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MONITORING; HUMAN; IMMUNOLOGICAL TOLERANCE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SINGLE BLIND PROCEDURE; SWINE; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL FRACTURES; FLUID THERAPY; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; INFUSIONS, INTRAVENOUS; MALE; RANDOM ALLOCATION; RESUSCITATION; SERUM ALBUMIN, BOVINE; SINGLE-BLIND METHOD; SWINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN;

EID: 2942739032     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000127770.29009.5A     Document Type: Article

References (33)

1. Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci USA. 1975;72:11-15.
2. Ozkaynak E, Finley D, Varshavsky A. The yeast ubiquitin gene: head-to-tail repeats encoding a polyubiquitin precursor protein. Nature. 1984;312:663-666.
3. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425-479.
4. Pickart CM. Ubiquitin enters the new millennium. Mol Cell. 2001;8:499-504.
5. Hasselgren PO, Fischer JE. The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Ann Surg. 1997;225:307-316.
6. Seufert W, Jentsch S. In vivo function of the proteasome in the ubiquitin pathway. EMBO J. 1992;11:3077-3080.
7. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol. 2002;1:20-26.
8. Schnell JD, Hicke L. Non-traditional functions of ubiquitin and ubiquitin-binding proteins. J Biol Chem. 2003;278:35857-35860.
9. Asseman C, Pancre V, Delanoye A, Capron A, Auriault C. A radioimmunoassay for the quantification of human ubiquitin in biological fluids: application to parasitic and allergic diseases. J Immunol Methods. 1994;173:93-101.
10. Takagi M, Yamauchi M, Toda G, Takada K, Hirakawa T, Ohkawa K. Serum ubiquitin levels in patients with alcoholic liver disease. Alcohol Clin Exp Res. 1999;23(4 suppl):76S-80S.
11. Akarsu E, Pirim I, Capoglu I, Deniz O, Akcay G, Unuvar N. Relationship between electroneurographic changes and serum ubiquitin levels in patients with type 2 diabetes. Diabetes Care. 2001;24:100-103.
12. Okada M, Miyazaki S, Hirasawa Y. Increase in plasma concentration of ubiquitin in dialysis patients: possible involvement in beta 2-microglobulin amyloidosis. Clin Chim Acta. 1993;220:135-144.
13. Akarsu E, Pirim I, Selcuk NY, Tombul HZ, Cetinkaya R. Relation between serum ubiquitin levels and KT/V in chronic hemodialysis patients. Nephron. 2001;88:280-282.
14. Pancre V, Pierce RJ, Fournier F, et al. Effect of ubiquitin on platelet functions: possible identity with platelet activity suppressive lymphokine (PASL). Eur J Immunol. 1991;21:2735-2741.
15. Nakamura M, Xavier RM, Tanigawa Y. Ubiquitin-like moiety of the monoclonal nonspecific suppressor factor beta is responsible for its activity. J Immunol. 1996;156:532-538.
16. Daino H, Matsumura I, Takada K, et al. Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells. Blood. 2000;95:2577-2585.
17. Daino H, Shibayama H, Machii T, Kitani T. Extracellular ubiquitin regulates the growth of human hematopoietic cells. Biochem Biophys Res Commun. 1996;223:226-228.
18. Kieffer AE, Goumon Y, Ruh O, et al. The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities. FASEB J. 2003;17:776-778. Epub February 19, 2003.
19. Majetschak M, Krehmeier U, Bardenheuer M, et al. Extracellular ubiquitin inhibits the TNF-alpha response to endotoxin in peripheral blood mononuclear cells and regulates endotoxin hyporesponsiveness in critical illness. Blood. 2003;101:1882-1890. Epub October 24, 2002.
20. Majetschak M, Cohn SM, Nelson JA, Burton EH, Obertacke U, Proctor KG. Effects of exogenous ubiquitin in lethal endotoxemia. Surgery. 2004;135:538-545.
21. Moomey CB Jr, Melton SM, Croce MA, Fabian TC, Proctor KG. Prognostic value of blood lactate, base deficit, and oxygen-derived variables in an LD50 model of penetrating trauma. Crit Care Med. 1999;27:154-161.
22. Cerovic O, Golubovic VV, Spec-Marn A, Kremzar B, Vidmar G. Relationship between injury severity and lactate levels in severely injured patients. Intensive Care Med. 2003;29:1300-1305. Epub July 9, 2003.
23. Abramson D, Scalea TM, Hitchcock R, Trooskin SZ, Henry SM, Greenspan J. Lactate clearance and survival following injury. J Trauma. 1993;35:584-589.
24. Manikis P, Jankowski S, Zhang H, Kahn RJ, Vincent JL. Correlation of serial blood lactate levels to organ failure and mortality after trauma. Am J Emerg Med. 1995;13:619-622.
25. Fabian TC, Croce MA, Fabian MJ, et al. Reduced tumor necrosis factor production in endotoxin-spiked whole blood after trauma: experimental results and clinical correlation. Surgery. 1995;18:63-72.
26. Keel M, Schregenberger N, Steckholzer U, et al. Endotoxin tolerance after severe injury and its regulatory mechanisms. J Trauma. 1996;41:430-438.
27. Majetschak M, Flach R, Heukamp T, et al. Regulation of whole blood tumor necrosis factor production upon endotoxin stimulation after severe blunt trauma. J Trauma. 1997;3:880-887.
28. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991;88:1747-1754.
29. Ertel W, Kremer JP, Kenney J, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood. 1995;85:1341-1347.
30. Adrie C, Adib-Conquy M, Laurent I, et al. Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation. 2002;106:562-568.
31. Cinat M, Waxman K, Vaziri ND, et al. Soluble cytokine receptors and receptor antagonists are sequentially released after trauma. J Trauma. 1995;39:112-120.
32. Donnelly TJ, Meade P, Jagels M, et al. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med. 1994;22:768-776.
33. Hoch RC, Rodriguez R, Manning T, et al. Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med. 1993;21:839-845.